Coronavirus: AstraZeneca boss confident Covid-19 vaccine can succeed

Coronavirus: AstraZeneca boss confident Covid-19 vaccine can succeed

The head of the GAVI vaccine alliance also told a Swiss newspaper that first indications of the effectiveness of a potential vaccine against coronavirus may be available in the autumn, forecasting a long road from there to broad availability.

"Once the vaccine is ready it will go for animal trials to be followed by human clinical trials to assess its safety and efficacy which will take at least one year", a senior ICMR official told PTI.

Earlier this week, drugmaker AstraZeneca said it had secured its first agreements for 400 million doses of the Oxford-developed vaccine, bolstered by a NZ$1.6 billion investment from a United States government agency, for the development, production and delivery of the vaccine, starting in the fall.

The government projected that the vaccine, if successful, could deliver 30 million doses by September.

While there has not yet been a malaria vaccine, a colleague of Prof Hill, Professor Sarah Gilbert was able to modify the same chimpanzee virus to vaccinate against MERS, a coronavirus, which then progressed onto human trials in the UK.

The company said that it had received financial support of more than $1 billion from the US Biomedical Advanced Research and Development Authority (BARD) for the development, production, and delivery of the said vaccine.

'We have to run as fast as possible before the disease disappears so we can demonstrate that the vaccine is effective'.

The BBIL is working towards developing killed virus vaccine which usually provides good immunogenicity, the official said, adding that by entering the body it will create antibody against the infection.

Dalhousie says Canada's first clinical trial for a potential vaccine will start with fewer than 100 people between the ages of 18 and 55.

Adrian Hill, director of Oxford's Jenner Institute, said that an upcoming trial, involving 10,000 volunteers threatened to return "no result" due to low transmission of COVID-19 in the community.

"It's a race against the virus disappearing, and against time", Professor Hill, 61, told the Telegraph.

"At the moment, there's a 50% chance that we get no result at all", he said.

Leading virologist Shahid Jameel said India's vaccine manufacturing capacity is quite remarkable and at least three Indian companies - Serum Institute, Bharat Biotech and Biologicals E are at the forefont, working with global partners to manufacture a vaccine for COVID-19.

The jab is now called AZD1222 since a partnership was pharmaceutical giant AstraZeneca was secured in order to produce billions of doses.

With the country in lockdown this reduces the spread of the disease, making it harder for scientist to prove their vaccine has an impact.

Some 10,000 people are being recruited to test the jab over the coming weeks.

Phase one, which began in April, involved just over 1,000 adult volunteers aged 18-55, being inoculated, following promising results on six monkeys in the U.S. in late March.

Related Articles